그레이브스병의 내과적 치료

키워드

참고문헌 (36)

1. Cho BY, "Hyperthyroidism: Graves’ disease. Clinical thyroidolgy", pp.219~284 (2014), Korea Medical Book
2. Adams DD, "Abnormal responses in the assay of thyrotropin", Proc Univ Otago Med Sch, 34, pp.11~12 (1956)
3. Smith BR, "The thyroid-stimulating properties of long-acting thyroid stimulator gamma G-globulin subunits", Biochim Biophys Acta, 192(2), pp.277~285 (1969)
4. Hertz BE, "Saul Hertz, MD (1905-1950): a pioneer in the use of radioactive iodine", Endocr Pract, 16(4), pp.713~715 (2010)
5. Astwood EB, "Landmark article May 8, 1943: Treatment of hyperthyroidism with thiourea and thiouracil. By E.B. Astwood", JAMA, 251(13), pp.1743~1746 (1984)
6. Astwood EB, "Further studies on the chemical nature of compounds which inhibit the function of the thyroid gland", Endocrinology, 37, pp.456~481 (1945)
7. Codaccioni JL, "Lasting remissions in patients treated for Graves'hyperthyroidism with propranolol alone: a pattern of spontaneous evolution of the disease", J Clin Endocrinol Metab, 67(4), pp.656~662 (1988)
8. Wood LC, "Hypothyroidism as a late sequela in patient with Graves' disease treated with antithyroid agents", J Clin Invest, 64(5), pp.1429~1436 (1979)
9. Ross DS, "2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis", Thyroid, 26(10), pp.1343~1421 (2016)
10. Mazza E, "Long-term follow-up of patients with hyperthyroidism due to Graves' disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study", J Endocrinol Invest, 31(10), pp.866~872 (2008)
11. Abraham P, "A systematic review of drug therapy for Graves' hyperthyroidism", Eur J Endocrinol, 153(4), pp.489~498 (2005)
12. Rotondi M, "Post-partum and non-post-partum relapsing Graves' hyperthyroidism display different response to anti-thyroid drugs", Eur J Endocrinol, 178(6), pp.589~594 (2018)
13. Solomon BL, "Remission rates with antithyroid drug therapy: continuing influence of iodine intake?", Ann Intern Med, 107(4), pp.510~512 (1987)
14. Hiraiwa T, "Restriction of dietary Iodine does not ameliorate the early effect of anti-thyroid drug therapy for Graves' disease in an area of excessive iodine intake", J Endocrinol Invest, 29(4), pp.380~384 (2006)
15. Park SM, "Excessive iodine intake does not increase the recurrence rate of graves' disease after withdrawal of the antithyroid drug in an iodine-replete area", Eur Thyroid J, 4(1), pp.36~42 (2015)
16. Kim TY, "Epitope heterogeneity of thyroid-stimulating antibodies predicts long-term outcome in Graves' patients treated with antithyroid drugs", J Clin Endocrinol Metab, 88(1), pp.117~124 (2003)
17. Choo YK, "Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease", Thyroid, 20(9), pp.949~954 (2010)
18. Prakash R, "Prediction of remission in Graves' disease treated with long-term carbimazole therapy: evaluation of technetium-99m thyroid uptake and TSH concentrations as prognostic indicators", Eur J Nucl Med, 23(2), pp.118~122 (1996)
19. Rittmaster RS, "Effect of methimazole, with or without L-thyroxine, on remission rates in Graves' disease", J Clin Endocrinol Metab, 83(3), pp.814~818 (1998)
20. Vos XG, "Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves' hyperthyroidism", J Clin Endocrinol Metab, 101(4), pp.1381~1389 (2016)
21. Quadbeck B, "Sensitive thyrotropin and thyrotropinreceptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves'disease", Thyroid, 15(9), pp.1047~1054 (2005)
22. Tun NN, "Thyrotropin receptor antibody levels at diagnosis and after thionamide course predict Graves' disease relapse", Thyroid, 26(8), pp.1004~1009 (2016)
23. 김원배, "갑상선자극호르몬 결합억제 면역글로불린(TBII) 측정법의 임상적 이용", Endocrinology and Metabolism, 23(3), pp.174~178 (2008), 대한내분비학회
24. 권혜미, "Usefulness of Measuring Thyroid Stimulating Antibody at the Time of Antithyroid Drug Withdrawal for Predicting Relapse of Graves Disease", Endocrinology and Metabolism, 31(2), pp.300~310 (2016), 대한내분비학회
25. Kahaly GJ, "European Thyroid Association guideline for the management of Graves' hyperthyroidism", Eur Thyroid J, 7(4), pp.167~186 (2018)
26. Takasu N, "Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment", Thyroid, 10(10), pp.891~896 (2000)
27. Brito JP, "Antithyroid drugs-the most common treatment for Graves' disease in the United States:a nationwide population-based study", Thyroid, 26(8), pp.1144~1145 (2016)
28. Tatara MR, "Effects of long-term oral administration of methimazole on femur and tibia properties in male Wistar rats", Biomed Pharmacother, 94, pp.124~128 (2017)
29. Azizi F, "Long-term antithyroid drug treatment:a systematic review and meta-analysis", Thyroid, 27(10), pp.1223~1231 (2017)
30. Leger J, "Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves' disease: national long-term cohort study", J Clin Endocrinol Metab, 97(1), pp.110~119 (2012)
31. Lippe BM, "Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years", J Clin Endocrinol Metab, 64(6), pp.1241~1245 (1987)
32. Azizi F, "Increased remission rates after long-term methimazole therapy in patients with Graves' disease: results of a randomized clinical trial", Thyroid, 29(9), pp.1192~1200 (2019)
33. Bandai S, "The long-term follow-up of patients with thionamide-treated Graves' hyperthyroidism", Endocr J, 66(6), pp.535~545 (2019)
34. El Fassi D, "B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study", J Clin Endocrinol Metab, 92(5), pp.1769~1772 (2007)
35. Pearce SHS, "Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves' hyperthyroidism: a phase I study", Thyroid, 29(7), pp.1003~1011 (2019)
36. Furmaniak J, "In vivo effects of a human thyroid-stimulating monoclonal autoantibody (M22) and a human thyroid-blocking autoantibody (K1-70)", Auto Immun Highlights, 3(1), pp.19~25 (2012)

관련 논문AI추천